FGF9 and neoplasm: Moreover, the prevalence of FGF9 high-expression group was significantly increased in CAFs than that in tumor cells not only in primary tumor but also in lymph node metastatic sites (Fig. 5i and j, 30.0% vs 11.9%, P < 0.01 and 32.1% vs 12.3%, P < 0.01, respectively).